Ultibro Breezhaler (indacaterol / glycopyrronium bromide)

Description

Ultibro Breezhaler is a fixed-dose combination medication containing indacaterol and glycopyrronium bromide. It is classified as an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA) and anticholinergic, working together to help those experiencing airway blockages. This medication is mainly used as a long-term maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), including conditions like chronic bronchitis and emphysema.

Directions

To properly use the Ultibro Breezhaler, follow the instructions provided by your healthcare professional and the guide included with the inhaler device. The standard dosage for this medication is one inhalation of the combined glycopyrrolate 15.6 mcg-indacaterol 27.5 mcg capsule, taken twice a day, once in the morning and once in the evening. Ensure you use the Ultibro Breezhaler consistently and avoid taking more than the prescribed dose. To get the most benefit from the medication, use it at the same time each day.

Ingredients

Ultibro Breezhaler is a medication containing two active substances: indacaterol (85 micrograms) and glycopyrronium (43 micrograms).

Contraindications

Avoid taking or using Ultibro Breezhaler if any of the following apply:

• Allergy to indacaterol maleate or glycopyrronium bromide
• Allergy to any other component of the Ultibro Breezhaler
• Allergy to any ingredient in the formulation, including non-medicinal ingredients
• Children under 18. This medication is only approved for use in adults.

Cautions

• Before starting Ultibro Breezhaler, inform your doctor about:
• Any medications you take.
• Any medical conditions.
• Pregnancy or plans to become pregnant.
• Breastfeeding or plans to breastfeed.

• Avoid using Ultibro Breezhaler with other long-acting beta-adrenergic agonists or muscarinic antagonists, as it may lead to adverse drug interactions.
• Ultibro Breezhaler should not be used to treat asthma, as it could increase the risk of serious asthma-related events, including death.
• Do not use Ultibro Breezhaler to treat sudden episodes of bronchospasm. Seek immediate medical attention if acute symptoms occur.
• If you experience signs of an allergic reaction such as swelling or skin rash, discontinue use immediately and consult a healthcare provider for alternative treatments.
• If using Ultibro Breezhaler leads to worsening of breathing problems, stop usage immediately and seek alternative therapy.
• Patients with narrow-angle glaucoma should use Ultibro Breezhaler cautiously and remain alert to any worsening of symptoms.
• Caution is advised for patients with a history of urinary retention.
• Those with severe kidney problems should only use Ultibro Breezhaler if the benefit justifies the risk, and such patients should be monitored for adverse effects.
• Patients with cardiovascular conditions should use Ultibro Breezhaler with caution due to the potential for increased heart rate, blood pressure, and ECG changes.
• Monitor potassium levels as beta-adrenergic agonists can cause low potassium levels, potentially leading to cardiovascular issues.
• If you have diabetes, you may need to monitor blood sugar levels more closely when starting Ultibro Breezhaler, as it may cause low blood sugar levels.
• People with seizure disorders, thyroid issues, or heightened responsiveness to beta2-adrenergic agonists should use caution.
• Ultibro Breezhaler contains lactose; those with lactose-related hereditary problems may need to avoid this medication.

Side Effects

Ultibro Breezhaler may cause side effects in some individuals. Common side effects may include cough, sore throat, headache, and runny nose. Additionally, some people may experience dizziness, trouble sleeping, and indigestion. More serious side effects of Ultibro Breezhaler may include cardiovascular effects like heart rhythm problems and fast heartbeat. If someone taking Ultibro Breezhaler experiences any of these serious side effects, it is important to seek medical advice immediately.

References:

1. Ultibro Breezhaler (indacaterol / glycopyrronium bromide) Product Monograph. Nuremburg, Germany: Novartis Pharmaceuticals; 2018.
2. Ultibro Breezhaler (indacaterol / glycopyrronium bromide) Full Prescribing Information. MIMS; 2023.

About Dr. Gerardo Sison (Page Author)

An honors graduate of the University of Florida, Dr. Sison started his pharmacy career in a community setting, extending his services to hospitals and clinics over time. He has also worked in medication therapy management, advising patients on proper medication use for their chronic health conditions. Read More....